Overview of Pro Medicus Ltd’s Performance
Pro Medicus Ltd (ASX: PME) has experienced a significant decline in its share price over the past year, with a drop of 56%. This is evident from the chart provided. However, some experts believe that the company may have been oversold, and there could be potential for recovery.
The business model of Pro Medicus involves providing medical imaging and services software to clients such as hospitals, imaging centres, and healthcare groups. These clients are considered defensive, meaning that demand for their services remains consistent throughout the year, regardless of economic conditions.
Looking ahead, Pro Medicus has a positive outlook for both revenue and profit growth. This could help restore investor confidence in the company. Let’s explore how undervalued the business might be.
Share Price Targets
A share price target is an analyst’s estimate of where the share price could go within the next 12 months. It is based on various factors, including the company’s fundamentals, but it is not a guaranteed return.
According to CMC Invest, there have been eight ratings on Pro Medicus within the last three months. Out of these, seven were “buy” ratings, and one was a “hold.” The average price target of these eight ratings is $196.73, suggesting a possible rise of 61% in the next year from the current price at the time of writing.
The most optimistic price target is $241.89, which implies that the Pro Medicus share price could nearly double within the next year. On the other end of the spectrum, the lowest price target is $143.14, still indicating a possible increase of 17%.
Valuation Considerations
When evaluating a company, it is important to consider its price/earnings (P/E) ratio. This helps determine whether the company is attractive based on its potential earnings growth.
While it is challenging to predict the impact of AI competitors on the software industry, analysts remain optimistic about Pro Medicus’s potential. According to projections from CMC Invest, the company is expected to generate earnings per share (EPS) of $1.372 in FY26 and $1.863 in FY27.
This means that the company is valued at 89x FY26’s estimated earnings and 65x FY27’s estimated earnings. The projection also suggests that EPS could grow by 35.8% year-over-year in FY27.
If Pro Medicus continues to attract new customers and renew contracts on better terms, while maintaining an underlying operating profit (EBIT) margin above 70%, then its net profit could see a significant increase. This could justify the most optimistic analysts’ projections.
Investment Considerations
Before investing in Pro Medicus shares, it is essential to consider various factors. Motley Fool investing expert Scott Phillips has highlighted what he believes are the five best stocks for investors to buy right now, and Pro Medicus was not among them.
The online investing service run by Scott, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have seen substantial returns. Currently, Scott believes there are five stocks that may offer better investment opportunities.
Additional Reading
For further insights into Pro Medicus, you can explore related articles:
- Pro Medicus inks $90m contract
- 2 beaten-down ASX shares to hold until 2036
- 3 amazing ASX growth shares to buy and hold forever
- ASX tech shares vs. ATEC ETF: How they fared during sector downturn
- 9 ASX 200 shares with renewed buy calls from the experts this week
Tristan Harrison, a Motley Fool contributor, has positions in Pro Medicus. The Motley Fool Australia’s parent company, Motley Fool Holdings Inc., has recommended Pro Medicus. The Motley Fool Australia has also recommended Pro Medicus. The Motley Fool has a disclosure policy. This article provides general investment advice only (under AFSL 400691). It has been authorised by Scott Phillips.
